Scolaris Content Display Scolaris Content Display

Natriuretic peptide‐guided treatment for the prevention of cardiovascular events in patients without heart failure

This is not the most recent version

References

Additional references

Clerico 2007

Clerico A, Fontana M, Zyw L, Passino C, Emdin M. Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the n‐terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. Clinical Chemistry 2007;53(5):813‐22.

Deeks 2017

Deeks JJ, Higgins JP, Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking metaanalyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.

Ebrahim 2011

Ebrahim S, Taylor F, Ward K, Beswick A, Burke M, Smith D. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database of Systematic Reviews 2011, Issue 1. [DOI: 10.1002/14651858.CD001561.pub3]

Eurlings 2010

Eurlings L, van Pol P, Kok W, van Wijk S, Lodewijks‐van der Bolt C, Balk A, et al. Management of chronic heart failure guided by individual n‐terminal pro‐b‐type natriuretic peptide targets: results of the PRIMA (Can PRo‐brain‐natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. Journal of the American College of Cardiology 2010;56(25):2090‐100.

Gardner 2003

Gardner R, Ozalp F, Murday A, Robb S, McDonagh T. N‐terminal pro‐brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. European Heart Journal 2003;24:1735–43.

Glaser 2011

Glaser R, Peacock WF, Wu AH, Muller R, Möckel M, Apple FS. Placental growth factor and b‐type natriuretic peptide as independent predictors of risk from a multibiomarker panel in suspected acute coronary syndrome (Acute Risk and Related Outcomes assessed With cardiac biomarkers [ARROW]) study. American Journal of Cardiology 2011;107(6):821‐6.

Go 2104

Go A, Mozaffarian D, Roger V, Benjamin E, Berry J, Blaha M, et al. Heart disease and stroke statistics. 2014 update: a report from the American Heart Association. Circulation 2014;129(3):228‐92.

GRADEpro GDT 2015 [Computer program]

McMaster University (developed by Evidence Prime). GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.

HERC 2012

Health Economics Research Centre. CVD costs in Europe: the economic burden of cardiovascular disease in the enlarged European Union. www.herc.ox.ac.uk/research/disease‐cost‐studies‐1/studies‐14/cvd‐costs‐in‐europe‐the‐economic‐burden‐of‐cardiovascular‐disease‐in‐the‐enlarged‐european‐union‐1 (accessed 21 July 2016).

Higgins 2017

Higgins JP, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.

Kearley 2011

Kearley K, Wright F, Tyndel S, Roberts N, Perera R, Glasziou P, et al. B‐type natriuretic peptide‐guided treatment for heart failure. Cochrane Database of Systematic Reviews 2011, Issue 1. [DOI: 10.1002/14651858.CD008966]

Kip 2008

Kip KE, Hollabaugh K, Marroquin OC, Williams DO. The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. Journal of the American College of Cardiology 2008;51(7):701‐7.

Krogsbøll 2012

Krogsbøll L, Jørgensen K, Grønhøj Larsen C, Gøtzsche P. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD009009.pub2]

Lefebvre 2011

Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Liberati 2009

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009;6(7):e1000100.

Lloyd‐Jones 2006

Lloyd‐Jones D, Leip E, Larson M, D'Agostino R, Beiser A, Wilson P, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006;133(6):791‐8.

Maeda 1998

Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end‐diastolic pressure in patients with symptomatic left ventricular dysfunction. American Heart Journal 1998 May;135(5):825‐32.

McGrady 2013

McGrady M, Reid C, Shiel L, Wolfe R, Boffa U, Liew D, et al. N‐terminal b‐type natriuretic peptide and the association with left ventricular diastolic function in a population at high risk of incident heart failure: results of the SCReening Evaluation of the Evolution of New‐Heart Failure Study (SCREEN‐HF). European Journal of Heart Failure 2013;14:573‐80.

McKee 1971

McKee AP, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham Study. New England Journal of Medicine 1971;285(26):1441‐6.

Mishra 2014

Mishra RK, Beatty AL, Jaganath R, Regan M, Wu AHB, Whooley MA. B‐type natriuretic peptides for the prediction of cardiovascular events in patients with stable coronary heart disease: the heart and soul study. Journal of the American Heart Association 2014;3(4):1‐9.

Moe 2015

Moe G, Ezekowitz J, O'Meara E, Lepage S, Howlett J, Fremes S, et al. The 2014 Canadian Cardiovascular Society heart failure management guidelines focus update: anemia, biomarkers, and recent therapeutic trial implications. Canadian Journal of Cardiology 2015;31(1):3‐16.

Nichols 2014

Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. European Heart Journal 2014;35(42):2950‐9.

Onodera 2012

Onodera M, Nakamura M, Tanaka F, Takahashi T, Makita S, Ishisone T, et al. Plasma b‐type natriuretic peptide is useful for cardiovascular risk assessment in community‐based diabetes subjects: comparison with albuminuria. International Heart Journal 2012;53(3):176‐81.

Phelan 2012

Phelan D, Watson C, Martos R, Collier P, Patle A, Donnelly S, et al. Modest elevation in BNP in asymptomatic hypertensive patients reflects sub‐clinical cardiac remodeling, inflammation and extracellular matrix changes. PLoS One 2012;7(11):e49259.

Piepoli 2016

Piepoli M, Hoes A, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal 2016;37(29):2315‐81.

Ponikowski 2016

Ponikowski P, Voors A, Anker S, Bueno H, Cleland J, Coats A, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal 14 Jul 2016;37(27):2129‐200.

Raymond 2003

Raymond I, Groenning B, Hildebrandt P, Nilsson J, Baumann M, Trawinski J, et al. The influence of age, sex and other variables on the plasma level of n‐terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003;89(7):745‐51.

Review Manager 2014 [Computer program]

Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

Ryan 2016

Ryan R. Heterogeneity and subgroup analyses in Cochrane Consumers and Communication Group reviews: planning the analysis at protocol stage. cccrg.cochrane.org (accessed 09 April 2018).

Sabatine 2004

Sabatine M, Morrow D, de Lemos J, Omland T, Desai M, Tanasijevic M, et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. Journal of the American College of Cardiology 2004;44(10):1988‐95.

Santulli 2013

Santulli G. Epidemiology of cardiovascular disease in the 21st century: Updated numbers and updated facts. Journal of Cardiovascular Disease 2013;1(1):2326‐3121.

Scirica 2011

Scirica BM, Sabatine MS, Jarolim P, Murphy SA, de Lemos JL, Braunwald E, et al. Assessment of multiple cardiac biomarkers in non‐ST‐segment elevation acute coronary syndromes: observations from the MERLIN‐TIMI 36 Trial. European Heart Journal 2011;32(6):697‐705.

Sedgwick 2013

Sedgwick, P. Selection bias versus allocation bias. British Medical Journal 2013;346:f1342.

Tarnow 2006

Tarnow L, Gall M, Hansen B, Hovind P, Parving H. Plasma n‐terminal pro‐b‐type natriuretic peptide and mortality in type 2 diabetes. Diabetologia 2006;49:2256–326.

Wang 2002

Wang T, Larson M, Levy D, Leip E, Benjamin E, Wilson P, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. American Journal of Cardiology 2002;90(3):254‐8.

Wang 2004

Wang T, Larson M, Levy D, Benjamin E, Leip E, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. New England Journal of Medicine 2004;350(7):655‐63.

WHO 2016

World Health Organization. Cardiovascular diseases fact sheet. www.who.int/mediacentre/factsheets/fs317/en/ (accessed 21 July 2016).

Yancy 2013

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128(16):240‐327.

Yancy 2017

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017;136:137‐61.

Yoshimura 1993

Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, Mukoyama M, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993;87:464‐9.
Table 1. 'Summary of findings' table ‐ draft

Natriuretic peptide‐based screening and subsequent NP‐guided treatment compared to standard care for prevention of cardiovascular mortality and hospitalisation in those with cardiovascular risk factors

Patient or population: people with cardiovascular risk factors
Setting: any
Intervention: natriuretic peptide‐based screening and subsequent NP‐guided treatment
Comparison: standard care

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

№ of participants
(studies)

Certainty of the evidence
(GRADE)

Comments

Risk with standard care

Risk with NP‐based screening and subsequent NP‐guided treatment

Cardiovascular mortality

Cardiovascular hospitalisation

Ventricular dysfunction

All‐cause hospitalisations (all occurrences)

All‐cause mortality

NP level at the end of follow‐up

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; RR: risk ratio; OR: odds ratio;

GRADE Working Group grades of evidence
High‐certainty: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate‐certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low‐certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect
Very low‐certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect

Figures and Tables -
Table 1. 'Summary of findings' table ‐ draft